MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Active, not recruiting · Phase 1 · NCT06586515
Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
At a glance
- Research payments reported, 2025
- $4.4M
- U.S. investigators named
- 25
- Sites paid
- 21
- Planned or actual enrollment
- 630
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3962673 (drug), Cetuximab (drug), Gemcitabine (drug), nab-paclitaxel (drug), Oxaliplatin (drug), leucovorin (drug), Irinotecan (drug), 5-fluorouracil (drug)
- Dates
- Started 2024-09-12; completion 2028-03
- Results posted
- Not yet
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.
From ClinicalTrials.gov, last updated 2026-10-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $4.4M in research payments for this study in 2025 (25 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Aditya V. Shreenivas, MD Medical Oncology · Duarte, CA
- Vivek Subbiah, MD Medical Oncology · Stanford, CA
- Zev A. Wainberg, MD Hematology & Oncology · Santa Monica, CA
- Jason Henry, M.D Internal Medicine · Denver, CO
- Michael J. Pishvaian, MD Medical Oncology · Washington, DC
- Ignacio Garrido-laguna, MD Medical Oncology · Tampa, FL
- Cesar A. Perez Batista, M.D. Medical Oncology · Orlando, FL
- John H. Strickler, MD Hematology & Oncology · Jacksonville, FL
- Olatunji B. Alese, M.D. Medical Oncology · Atlanta, GA
- Elena G. Chiorean, M.D. Medical Oncology · Chicago, IL
- Natraj R. Ammakkanavar, M.D Medical Oncology · Indianapolis, IN
- Brandon M. Huffman, M.D. Hematology & Oncology · Boston, MA
- Mohammed N. Al Hallak, M.D. Hematology & Oncology · Detroit, MI
- Nehal J. Lakhani, M.D. Hematology & Oncology · Grand Rapids, MI
- Paul E. Oberstein, MD Medical Oncology · New York, NY
- Anupriya Singhal, MD, PHD Medical Oncology · New York, NY
- Dennis Hsu, MD Medical Oncology · Columbus, OH
- Wen Wee Ma, MD Medical Oncology · Cleveland, OH
- Davendra P. Sohal, MD, MPH Hematology & Oncology · Cincinnati, OH
- Dana B. Cardin, MD Hematology & Oncology · Nashville, TN
- Jason Henry, PA Physician Assistants · Nashville, TN
- David S. Hong, M.D. Medical Oncology · Houston, TX
- Amita Patnaik, M.D. Medical Oncology · San Antonio, TX
- Vaia Florou, MD Hematology & Oncology · Salt Lake City, UT
- Dustin A. Deming, M.D. Medical Oncology · Madison, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sarah Cannon Research Institute LLC $795,742
- New York University $505,664
- Start Ctr for Cancer Care $281,600
- Ut MD Anderson Cancer Center $280,780
- City of Hope National Medical Ctr $265,630
- Dana Farber PArtners Cancer Care Inc $265,026
- Ronald Reagan UCLA Medical Center, CA $253,877
- Duke University $247,982
- Johns Hopkins University $189,384
- University of Utah Hospital and Clinics, UT $160,719
- University of Cincinnati $152,205
- University of Washington Medical Ctr, WA $149,916
- South Texas Accelerated Research Therapeutics LLC $141,382
- Community Hospital East, IN $125,604
- Emory University Hospital, GA $125,251
- Cleveland Clinic, OH $98,048
- Karmanos Cancer Center, MI $88,899
- Board of Regents of the Univ of Wisconsin Systm $87,412
- Univ of Pittsburgh Cancer Institute Cancer Srvcs $85,363
- Memorial Sloan-Kettering $73,706
- Vanderbilt University Medical Center, TN $71,185
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.